Udenafil - CISMeF

Preferred Label : Udenafil;

NCIt synonyms : 3-(1-methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-{2-[(2RS)-1-methylpyrrolidin-2-yl]ethyl}-4-propoxybenzenesulfonamide; Benzenesulfonamide, 3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methyl-2-pyrrolidinyl)ethyl]-4-propoxy-;

NCIt definition : A benzenesulfonamide derivative with vasodilatory activity. Udenafil selectively inhibits phosphodiesterase type 5 (PDE5), thus inhibiting the degradation of cyclic guanosine monophosphate (cGMP) found in the smooth muscle of the corpus cavernosa and corpus spongiosum of the penis; inhibition of cGMP degradation results in prolonged muscle relaxation, vasodilation, and blood engorgement of the corpus cavernosa, and, so, prolonged penile erection. This agent does not significantly inhibit the PDE11 isozyme; PDE11 inhibition may be associated with significant myalgia.;

UNII : L5IB4XLY36;

InChIKey : IYFNEFQTYQPVOC-UHFFFAOYSA-N;

CAS number : 268203-93-6;

Drug name : Zydena;

Molecule name : DA-8159;

Chemical formula : C25H36N6O4S;

Details

Origin ID

C74086;

UMLS CUI

C1742789;

Automatic exact mappings (from CISMeF team)
- Udenafil [ICD-11 Extension code]
Currated CISMeF NLP mapping
- udenafil [MeSH concept]
- udenafil [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- udenafil [ATC Code]
- udenafil [MeSH concept]
- udenafil [MeSH Supplementary Concept]
Validated automatic mappings to BTNT
- udenafil [ATC Code]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients